2024 World Conference on Lung Cancer (WCLC) - Posters-P4.14C.06 Effect of Cytotoxic Chemotherapy Following Ipilimumab Puls Nivolumab Combination Therapy for Malignant Pleural Mesothelioma

P4.14C.06 Effect of Cytotoxic Chemotherapy Following Ipilimumab Puls Nivolumab Combination Therapy for Malignant Pleural Mesothelioma

Back to course

Pdf Summary

The document is a study conducted by a team from the Hyogo Medical University's Department of Respiratory Medicine and Hematology. It evaluates the effects of second-line cytotoxic chemotherapy on patients with malignant pleural mesothelioma (MPM) who were initially treated with a combination of ipilimumab and nivolumab. This dual immunotherapy has been an approved first-line treatment for MPM in Japan since June 2021, as determined by the outcomes of the Checkmate743 trial.<br /><br />The study retrospectively examines patient cases from June 2021 to January 2024, specifically focusing on those who exhibited disease progression following initial immunotherapy. A subset of these patients received a second-line treatment consisting of a combination of platinum and pemetrexed chemotherapy.<br /><br />Patient demographics include a median age of 71, with a majority (69.6%) being male. MPM localization was more frequent in the right lung than the left, and the majority had epithelioid histology, with Stage 1 being the most prevalent stage at diagnosis.<br /><br />The effectiveness of the first-line treatment showed a 36.4% partial response (PR) rate, 36.4% stable disease (SD) rate, and a disease control rate (DCR) of 72.8%. For the second-line treatment, the PR rate dropped to 9.1%, SD functioned at 40.9%, with a DCR of 50%.<br /><br />Key results include a median progression-free survival (mPFS) of 4.7 months for the second-line therapy, with a 1-year progression-free survival rate of 29.7%. The median overall survival (mOS) wasn't reached yet, with a 1-year overall survival rate of 78.8%.<br /><br />The conclusion drawn suggests that the effectiveness of the second-line chemotherapy regime post-immunotherapy is comparable with the first-line cisplatin plus pemetrexed treatment outcome reported in the EMPHACIS study, which yielded a mPFS of 5.7 months.

Asset Subtitle

Koji Mikami

Meta Tag

Speaker Koji Mikami

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

malignant pleural mesothelioma

second-line chemotherapy

ipilimumab

nivolumab

Checkmate743 trial

platinum and pemetrexed

progression-free survival

overall survival

Hyogo Medical University

retrospective study